Inhibikase Therapeutics Inc (IKT) Stock Price & News

Analyst	Recommendation	Action	Price target	Projected	Date
Gaurav Maini LifeSci Capital	Buy	Maintained	$5.00	+157.7%	09/15/2026
Jason McCarthy Maxim Group	Buy	Maintained	$8.00	+312.4%	08/13/2026
Mazahir Alimohamed Oppenheimer	Buy	Maintained	$5.00	+157.7%	08/12/2026
Ram Selvaraju H.C. Wainwright	Buy	Reiterated	$8.00	+312.4%	07/31/2026
Jason Zemansky Bank of America Securities	Buy	Maintained	$6.00	+209.3%	07/27/2026
Olivia Brayer Cantor Fitzgerald	Buy	Maintained	$4.00	+106.2%	05/18/2026
Aydin Huseynov Ladenburg Thalmann & Co.	Buy	Initiated	$4.00	+106.2%	03/04/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	7.65M	-23.43M	-	-
Cost of revenue	7.65M	-23.43M	-	-
Research and development expenses	-	22.39M	10.84M	13.39M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	5.61M	6.77M	7.38M	7.66M
Operating expense	5.61M	29.17M	18.22M	21.05M
Total operating expenses	13.26M	5.73M	18.22M	21.05M
Operating income	-13.26M	-5.73M	-18.22M	-21.05M
Other non operating income	-	-	1.46M	1.46M
EBT including unusual items	-11.93M	-12.73M	-16.38M	-19.59M
EBT excluding unusual items	-12.42M	-4.69M	-16.75M	-19.59M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-11.93M	-12.73M	-16.38M	-19.59M
Net profit margin	-	-	-	-
Earnings per share	-	-	-0.10	-0.11
Interest and investment income	838.09K	1.04M	-	-
Interest expense	-	-	-	-
Net interest expenses	838.09K	1.04M	-	-
Depreciation and amortization charges	-	-	-	-
EBITDA	-13.24M	-5.73M	-18.20M	-21.04M
Gain or loss from assets sale	-	-	-	-

Finance